

# Alexander Treiber

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3535112/publications.pdf>

Version: 2024-02-01

14  
papers

900  
citations

840776

11  
h-index

1058476

14  
g-index

14  
all docs

14  
docs citations

14  
times ranked

905  
citing authors

#	ARTICLE	IF	CITATIONS
1	The Quest for the Best Dual Orexin Receptor Antagonist (Daridorexant) for the Treatment of Insomnia Disorders. <i>ChemMedChem</i> , 2020, 15, 2286-2305.	3.2	28
2	The endothelin receptor antagonist macitentan for the treatment of pulmonary arterial hypertension: A cross-species comparison of its cytochrome P450 induction pattern. <i>Pharmacology Research and Perspectives</i> , 2020, 8, e00619.	2.4	2
3	From Oxadiazole to Triazole Analogues: Optimization toward a Dual Orexin Receptor Antagonist with Improved in vivo Efficacy in Dogs. <i>ChemMedChem</i> , 2020, 15, 430-448.	3.2	4
4	The Use of Physiology-Based Pharmacokinetic and Pharmacodynamic Modeling in the Discovery of the Dual Orexin Receptor Antagonist ACT-541468. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2017, 362, 489-503.	2.5	56
5	Discovery of Highly Potent Dual Orexin Receptor Antagonists via a Scaffold-Hopping Approach. <i>ChemMedChem</i> , 2016, 11, 2132-2146.	3.2	14
6	The metabolism of the dual endothelin receptor antagonist macitentan in rat and dog. <i>Xenobiotica</i> , 2016, 46, 253-267.	1.1	6
7	Physiologically-Based Pharmacokinetic Modeling of Macitentan: Prediction of Drug-Drug Interactions. <i>Clinical Pharmacokinetics</i> , 2016, 55, 369-380.	3.5	23
8	Substituted pyrrolidin-2-ones: Centrally acting orexin receptor antagonists promoting sleep. Part 2. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 1884-1891.	2.2	30
9	Structure-Activity Relationship, Biological, and Pharmacological Characterization of the Proline Sulfonamide ACT-462206: a Potent, Brain-Penetrant Dual Orexin 1/Orexin 2 Receptor Antagonist. <i>ChemMedChem</i> , 2014, 9, 2486-2496.	3.2	33
10	Macitentan Does Not Interfere with Hepatic Bile Salt Transport. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2014, 350, 130-143.	2.5	33
11	Absorption, distribution, metabolism, and excretion of macitentan, a dual endothelin receptor antagonist, in humans. <i>Xenobiotica</i> , 2012, 42, 901-910.	1.1	69
12	N-Glycine-sulfonamides as potent dual orexin 1/orexin 2 receptor antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 5729-5733.	2.2	30
13	Pharmacology of Macitentan, an Orally Active Tissue-Targeting Dual Endothelin Receptor Antagonist. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2008, 327, 736-745.	2.5	288
14	Bosentan Is a Substrate of Human OATP1B1 and OATP1B3: Inhibition of Hepatic Uptake as the Common Mechanism of Its Interactions with Cyclosporin A, Rifampicin, and Sildenafil. <i>Drug Metabolism and Disposition</i> , 2007, 35, 1400-1407.	3.3	284